Avacta's AI-Powered Cancer Therapy Shows Edge Over Blockbuster Drug

LONDON and PHILADELPHIA – February 24, 2026 – UK-based Avacta Therapeutics has unveiled compelling preclinical data suggesting its novel cancer therapy platform, pre|CISION®, may hold significant advantages over one of the industry's most successful targeted cancer drugs. In an analysis driven by artificial intelligence, Avacta's drug candidate, AVA6103, demonstrated a faster, more concentrated, and more selective delivery of its payload to tumors compared to the blockbuster antibody-drug conjugate (ADC), Enhertu®.

The announcement marks a pivotal moment for Avacta, which is positioning its pre|CISION® technology as a next-generation solution designed to improve both the safety and effectiveness of potent cancer treatments. The company confirmed it is on track to initiate a Phase 1 clinical trial for AVA6103 in the first quarter of 2026, a critical step in translating these promising preclinical findings into potential patient benefits.

AI Reshapes the Battlefield in Drug Development

At the heart of Avacta's announcement is not just a new drug, but a novel method of comparison. Instead of conducting lengthy and costly head-to-head animal studies, the company employed an AI-driven approach to create a "synthetic comparator arm." This involved using AI to recreate a published dataset for Enhertu®, allowing for a direct digital comparison with experimental data from its own compound, AVA6103.

This methodology represents a significant shift in preclinical research, a field increasingly embracing computational power to accelerate discovery. The use of synthetic control arms is gaining traction across the pharmaceutical industry and with regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Such approaches can dramatically shorten development timelines and reduce reliance on animal testing, provided the underlying data is robust and the models are rigorously validated.

In a statement, Avacta CEO Christina Coughlin highlighted the dual significance of the findings. "This innovative use of AI to recreate a synthetic comparator arm also demonstrated the creativity and expertise of our team," she commented. The approach allowed for a direct comparison that might otherwise have been impractical.

While the "black box" nature of some AI models remains a topic of scientific discussion, the successful application of AI-generated evidence in supporting regulatory assessments for several approved drugs signals a growing acceptance. For companies like Avacta, leveraging AI is a strategic move to validate their technology more efficiently and build a stronger case for clinical investigation.

A Precision Strike: Aiming Beyond Current ADCs

Avacta's pre|CISION® platform is designed to solve a fundamental challenge in oncology: how to deliver a powerful poison to cancer cells while sparing healthy tissue. The current gold standard for this approach is the Antibody-Drug Conjugate (ADC), a class of "smart bombs" that have revolutionized cancer care. Enhertu®, co-developed by AstraZeneca and Daiichi Sankyo, is a leading example, having secured approvals for HER2-positive and HER2-low breast cancer, as well as certain lung and gastric cancers.

Despite their success, ADCs are not without drawbacks. Off-target toxicity can lead to severe side effects, with Enhertu® carrying a notable risk of potentially fatal interstitial lung disease (ILD). This has created an urgent need for therapies with an even better therapeutic window—maximizing tumor destruction while minimizing collateral damage.

This is the niche Avacta aims to fill. The pre|CISION® platform is not an ADC but a peptide-drug conjugate (PDC). It works by attaching a potent chemotherapy payload (in this case, an exatecan derivative similar to Enhertu's) to a unique peptide that is only cleaved by an enzyme called Fibroblast Activation Protein (FAP). Since FAP is highly abundant in the microenvironment of most solid tumors but scarce in healthy tissues, the drug is designed to be "switched on" almost exclusively at the tumor site.

The AI-powered comparison revealed three key potential advantages of this mechanism:

• Speed: AVA6103 reached its maximum concentration in the tumor within minutes of dosing, whereas Enhertu® took approximately 24 hours.
• Potency: The peak concentration of the active drug delivered by AVA6103 was more than a log (ten times) higher in the tumor than that observed with Enhertu®.
• Selectivity: The Tumor Selectivity Index (TSI)—a critical measure of how well a drug concentrates in the tumor versus the bloodstream—was nearly three-fold higher for Avacta's compound.

"Our analysis demonstrates three potential advantages of our proprietary pre|CISION delivery mechanism," Coughlin stated, emphasizing the more rapid penetration, higher tumor concentration, and superior selectivity. A higher TSI suggests that more of the drug is working where it's needed, which could translate into both greater efficacy and a more favorable safety profile for patients.

A Strategic Milestone on the Path to the Clinic

The positive data for AVA6103 serves as a crucial validation for Avacta's entire pre|CISION® platform. The company is already in the clinic with its first candidate, AVA6000, a FAP-activated version of the common chemotherapy drug doxorubicin. The progress of AVA6103, which uses a different and highly potent payload, strengthens the argument that the FAP-cleavage mechanism is a versatile and robust delivery system applicable to a range of cancer-killing agents.

Positioning AVA6103 against a market leader like Enhertu® is a bold strategic move. It immediately frames the technology not as an incremental improvement but as a potential disruptor in the multi-billion-dollar targeted therapy market. The focus on FAP as the trigger is also strategic, as the enzyme is widely expressed across many solid tumor types, including those where ADCs have struggled due to low or variable target antigen expression. Avacta's data suggests AVA6103 maintains high activity even in models with low FAP expression, a potentially key differentiator.

With a cash runway extending into the first quarter of 2026, Avacta appears financially prepared to advance AVA6103 into its planned Phase 1 trial. For investors and the broader oncology community, this trial will be the first true test of the platform's promise. The compelling preclinical data has, in the words of Coughlin, "significantly increased the probability of success."

The journey from a lab model to a patient's bedside is long and fraught with risk. However, by combining a clever biological mechanism with cutting-edge data science, Avacta has charted a promising course. The upcoming clinical trial will be watched closely to see if this precision-guided approach can deliver a new and better standard of care for cancer patients.